UK NICE issues positive recommendation for Zykadia (ceritinib) to treat ALK+ non small cell lung cancer- Novartis
UK's NICE has announced that Zykadia (ceritinib), from Novartis, has been recommended in line with its marketing authorisation, for the treatment of advanced ALK-positive non small cell lung cancer (NSCLC) in adults who have previously been treated with Pfizer's Xalkori (crizotinib). The regulator's decision is dependent on the continued provision of a patient access scheme, in which Novartis contnues to offer the drug to the NHS at a discounted price to ensure value for money. This is in contrast to the decision announced by NICE in November 2015.
Comment: Ceritinib is structurally distinct from crizotinib and has a 20-fold greater potency against the target than its more advanced rival, making it a prime candidate for use in resistant patients. Despite high initial responses to Xalkori therapy, patients usually acquire resistance to the drug and relapse within a year. Resistance mechanisms involved include ALK gene mutation, ALK gene amplification or activation of other tyrosine kinases such as EFGR. Approximately 2-7% of patients with NSCLC harbour the ALK gene rearrangement, which causes cancer growth.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma